Pay in 4 interest-free payments of $5.25 Learn more
Ships within 48 hours Β· Estimated delivery Aug 9 - Aug 14
W., Tan, K., & Febrinasari, R
doi: 10.1155/2022/1582432
A recent post hoc analysis of the CREDENCE (canagliflozin and renal events in diabetes with established nephropathy clinical evaluation) and DAPA-CKD (dapagliflozin and prevention of adverse outcomes in chronic kidney disease) trials found that SGLT-2 inhibitor use was associated with a lower rate of discontinuation of renin-angiotensin-aldosterone system inhibitors compared with placebo during follow-up in patients with albuminuric chronic kidney disease
Future research should aim to validate the clinical value of TCM compounds through large-scale, rigorously designed, and high-quality evidence-based studies
10.1371/journal.ppat.1004052 22 MooreD.DowhanD
The study was approved by the VT IRB, and informed consent was obtained from all participants prior to their participation in the study
US$ 23.45
US$ 24.00
US$ 24.43
US$ 29.68
US$ 22.46
US$ 25.43
US$ 29.54
